CoChat

Safety, tolerability, and seizure control during long‐term treatment with adjunctive brivaracetam for partial‐onset seizures

Open access
Toledo, Manuel, Whitesides, John, Schiemann, Jimmy, Johnson, Martin E., Eckhardt, Klaus, McDonough, Belinda, Borghs, Simon, Kwan, Patrick · 2016 · Epilepsia
Cited by 75

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Summary: Objectives: To report pooled safety/tolerability and seizure outcome data from adults with uncontrolled partial‐onset (focal) seizures (POS) receiving adjunctive brivaracetam (BRV) during phase IIb/III and long‐term follow‐up (LTFU) studies. Methods: Seizure outcome data were pooled from phase IIb (NCT00175929 and NCT00175825), III/IIIb (NCT00490035, NCT00464269, NCT00504881, and NCT01261325) and associated LTFU studies (NCT00175916, NCT00150800, and NCT01339559). Safety/tolerability data were pooled from these studies plus NCT01405508, NCT01653262, and NCT01728077 (LTFU). Patients received placebo (during core studies) or BRV 5–200 mg/day. Safety/tolerability and seizure outcomes (BRV modal doses 50–200 mg/day) were assessed until January 17, 2014. Results: Of 2,186 patients (97.3% with POS and 2.7% with other seizure types) who received BRV 50–200 mg/day, 2,051 (93.8%) completed core studies and continued in LTFU studies. Total BRV exposure: 5,339.4 patient‐years (≥8.0 years in 41 patients); 6‐, 12‐, 24‐, and 60‐month retention: 91.0%, 79.8%, 68.1%, and 54.4%, respectively. Safety/tolerability data pooled from 2,186 patients: ≥1 treatment‐emergent adverse event (TEAE) reported by 1,848 (84.5%) patients; 1,184 (54.2%) reported ≥1 TEAE considered treatment‐related. Most frequent TEAEs (≥10%): headache (20.9%), dizziness (17.5%), somnolence (15.2%), nasopharyngitis (13.2%), fatigue (11.3%), and convulsion (10.6%). Serious TEAEs (SAEs) and treatment‐related SAEs: 401 (18.3%) and 95 (4.3%) patients, respectively. Of 28 (1.3%) deaths, four (14.3%) were considered possibly treatment related by the investigator. Pooled seizure outcome data (1,836 patients): median POS frequency/28 days at baseline was 8.9; on treatment, median percentage reduction from baseline in POS/28 days was 48.8%, and ≥50% responder rate was 48.7%. Complete seizure freedom: 4.9%, 4.2%, 3.0%, and 3.3% for ≥6, 12, 24, and 60 months, respectively. Improvements were seen in health‐related quality of life (HRQoL) from baseline, assessed by Quality of Life in Epilepsy Inventory‐31. Significance: Adjunctive BRV treatment in adults with POS was effective and generally well tolerated when administered long‐term (≥8.0 years). Retention was high and HRQoL improvements were observed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/epi.13416

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 75

Metadata

Authors
Toledo, M., Whitesides, J., Schiemann, J., Johnson, M. E., Eckhardt, K., McDonough, B., Borghs, S., & Kwan, P.
Venue
Epilepsia
Publisher
Wiley
Published
2016-06-06
Volume
57
Issue
7
Pages
1139-1151
ISSN
  • 0013-9580 (ISSN-L)
  • 1528-1167
OpenAlex
W2419659369
Cited by
75
References
1
FWCI
6.73
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety, tolerability, and seizure control during long‐term treatment with adjunctive brivaracetam for partial‐onset seizures. https://app.cochat.ai/papers/10.1111/epi.13416
The paper
Toledo, M., Whitesides, J., Schiemann, J., Johnson, M. E., Eckhardt, K., McDonough, B., Borghs, S., & Kwan, P. (2016). Safety, tolerability, and seizure control during long‐term treatment with adjunctive brivaracetam for partial‐onset seizures. Epilepsia. https://doi.org/10.1111/epi.13416

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.